Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Total Liabilities : ¥1,601 Mil (As of Sep. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Zhongyuan Union Cell & Gene Engineering Total Liabilities?

Zhongyuan Union Cell & Gene Engineering's Total Liabilities for the quarter that ended in Sep. 2024 was ¥1,601 Mil.

Zhongyuan Union Cell & Gene Engineering's quarterly Total Liabilities increased from Mar. 2024 (¥1,590.09 Mil) to Jun. 2024 (¥1,593.76 Mil) and increased from Jun. 2024 (¥1,593.76 Mil) to Sep. 2024 (¥1,600.65 Mil).

Zhongyuan Union Cell & Gene Engineering's annual Total Liabilities increased from Dec. 2021 (¥1,500.62 Mil) to Dec. 2022 (¥1,630.97 Mil) but then declined from Dec. 2022 (¥1,630.97 Mil) to Dec. 2023 (¥1,612.74 Mil).

Zhongyuan Union Cell & Gene Engineering Total Liabilities Historical Data

The historical data trend for Zhongyuan Union Cell & Gene Engineering's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongyuan Union Cell & Gene Engineering Total Liabilities Chart

Zhongyuan Union Cell & Gene Engineering Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,427.82

1,440.80

1,500.62

1,630.97

1,612.74

Zhongyuan Union Cell & Gene Engineering Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															1,607.33	1,612.74	1,590.09	1,593.76	1,600.65

Zhongyuan Union Cell & Gene Engineering Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Zhongyuan Union Cell & Gene Engineering's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1481.737	+	(86.231	+	33.176
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	11.6)
	=	1,613

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5411.355	-	3798.611
	=	1,613

Zhongyuan Union Cell & Gene Engineering's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1481.844	+	(76.25	+	30.953
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	11.6)
	=	1,601

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	5280.484	-	3679.837
	=	1,601

Zhongyuan Union Cell & Gene Engineering Total Liabilities Related Terms

Thank you for viewing the detailed overview of Zhongyuan Union Cell & Gene Engineering's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhongyuan Union Cell & Gene Engineering Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhongyuan Union Cell & Gene Engineering Corp Ltd (SHSE:600645) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

45 East of Tianjin Airport Economic Zone nine, Tianjin, CHN, 300304

Website

http://www.vcanbio.com

Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.

Executives

Li De Fu	Director
Wang Xue Jun	senior management
Wang Yong	Director
Li Hai Bin	Director
He Wei	senior management
Li Qiang	senior management
Wu Ming Yuan	Director
Wang Hui	Director
Huang Jia Xue	senior management
Cao Hai Feng	Director
Han Yue E	Director
Liu Yong Jun	senior management
Cui Jing Xue	Supervisors
Yang Guang Xing	senior management
Meng Zhi Hong	senior management

Zhongyuan Union Cell & Gene Engineering Headlines

No Headlines